Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA )

3.100 +0.280 (+9.93%)
Streaming Delayed Price Updated: 2:10 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results 
Via News Direct
Exposures Product Safety
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the... 
Via TheNewswire.com
Exposures Product Safety
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Recap: Lisata Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics's Earnings Outlook
Via Benzinga
Earnings Preview: Lisata Therapeutics
Via Benzinga
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Achieves critical first step toward priority review voucher 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
From Virtual Investor Conferences
Via GlobeNewswire
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at NobleCon19 Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors... 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.